ABSTRACT As theophylline is known to stimulate lipolysis and lipid mobilisation, plasma concentrations of malonyl dialdehyde were studied in asthmatic patients being treated with sustained release theophylline. Malonyl dialdehyde was assessed as malonyl dialdehyde like material (MDA-LM) by the thiobarbituric acid assay. In a kinetic study (eight patients) plasma MDA-LM concentrations were found to be significantly higher after 30 than after eight days' treatment or before treatment, but not significantly different after 90 than after 30 days. In a comparative study (29 patients and 29 healthy volunteers) the mean plasma MDA-LM concentration was shown to be very significantly higher in the asthmatic group. The results are probably explained by an effect of theophylline on lipid peroxidation, and the effect of long term treatment on plasma MDA-LM merits further investigation.
Theophylline is now widely used in the long term treatment of bronchial asthma. The introduction of appropriately formulated sustained release theophylline preparations has offered a potential improvement in theophylline treatment, allowing maintenance of plasma theophylline concentrations in the range 10-15 mg/l over long periods. The clinical adverse effects of such long term treatment remain to be evaluated. Theophylline has been shown to exert a stimulating effect on the lipolytic process in adipose tissue in vitro and to stimulate lipolysis and lipid mobilisation in vivo. ' In this paper we report that long term treatment with theophylline increases the plasma concentration of malonyl dialdehyde.
Methods
Two sets of patients were studied. Firstly, we considered eight asthmatic patients who started treatment with sustained release theophylline and who In the kinetic study blood samples were taken before treatment and after eight days, one month, and three months of treatment. Two patients discontinued theophylline treatment at the third month; in these patients blood samples were taken again 15 days and 30 days after they had stopped the treatment.
Results

KINETIC STUDY
After eight days of treatment with sustained release theophylline plasma MDA-LM concentrations had risen slightly in seven of the eight patients (p < 0.05) (fig). After 30 days plasma MDA-LM concentrations were significantly higher than those observed at eight days or before the start of treatment (p < 0-01) (Wilcoxon signed rank sum test). After 90 days plasma MDA-LM concentrations had risen further in five patients and fallen in three, and for the group as a whole the concentrations were not significantly different from those observed at 30 days. In the two patients who discontinued treatment MDA-LM plasma concentrations had fallen after 15 days and had fallen further after 30 days. In the kinetic study group four patients had high MDA-LM concentrations (above 3 nmol/ml) before treatment (fig); two of these had been pregnant within two months of the study and two had received theophylline in the previous two months, using non-sustained-release tablets daily by mouth.
COMPARATIVE STUDY
The plasma MDA-LM concentration was significantly higher in the asthmatic group than in the control group (3.10 (SEM 0-10) and 2 52 (0.10) nmol/ml respectively: p < 0-001, Student's t test). Long term treatment with theophylline increases malonyl dialdehyde plasma concentrations observed in various physiological and pathological processes, such as pregnancy and toxaemia of pregnancy,3 radiation damage, vitamin E insufficiency, and aging.58 These associations of lipid peroxidation with pathological conditions do not necessarily imply that the process is directly concerned in pathogenesis.9 The effect of long term theophylline treatment on plasma MDA-LM, however, raises a question and deserves further investigation. 
